Evidence map›Paper›PMID 40594069›Full record

ArticleScientific reports2025

Pan-cancer analysis reveals ASCC family promotes the cancer progression of lung adenocarcinoma.

Yimin Pan, Jun Tan, Changwu Wu, Chunbo Liu, Zheng Chen, Yongye Zhu, Fushu Luo, Qing Liu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yimin PanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jun TanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Changwu WuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chunbo LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zheng ChenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yongye ZhuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fushu LuoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. 228102120@csu.edu.cn.
Qing LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. liuqingdr@csu.edu.cn.

Funding

China Postdoctoral Science Foundation 2022M723560China Postdoctoral Science Foundation 2023M733960National Key Research and Development Program of China 2022YFE0133400National Natural Science Foundation of China 82172834National Natural Science Foundation of China 82203397National Natural Science Foundation of China 82303253Nature Science Foundation of Changsha kq2202375Nature Science Foundation of Hunan Province 2022JJ40814Nature Science Foundation of Hunan Province 2024JJ6686Youth Foundation of Xiangya Hospital 2021Q06
6 · The paper itself

Abstract

The ASC-1 complex, consisting of TRIP4, ASCC1, ASCC2, and ASCC3, plays a pivotal role in regulating nuclear receptors and transcription factors that influence immunity, cellular proliferation, and apoptosis, and a multiomic analysis of ASCC1/2/3 was therefore performed to investigate its potential role on a pan-cancer scale. Although it has been implicated in DNA repair mechanisms and neurodegenerative diseases, its specific function within cancer biology remains poorly understood. This study conducted a pan-cancer analysis of ASCC1/2/3's roles in the tumorigenesis process and explored their regulatory effects on lung adenocarcinoma. We conducted a comprehensive analysis of 10,967 tumor samples across 30 distinct cancer types. It was found that alterations in ASCC1/2/3 occurred in 754 cases (7% of the patients analyzed), with ASCC3 being the most frequently altered at 4%. Furthermore, elevated expression levels of ASCC1/2/3 were observed in the majority of cancer types examined. Notably, the expression levels of ASCC1 and ASCC3 demonstrated a correlation with CD4-positive T cell infiltration. In vitro experiments demonstrated that the ASCC family effectively inhibited tumor proliferation, migration, and invasion in lung adenocarcinoma cell line. Our findings indicate a significant association between the ASCC family and tumors while providing a foundation for further investigation into its role in cancer biology and potential clinical applications.

Indexed as

Adenocarcinoma of LungCytoskeletal ProteinsLung NeoplasmsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansCytoskeletal ProteinsASC-1 complexASCC1/2/3Immune regulationLung adenocarcinomaTumor biology

Identifiers

PMID40594069
PMCPMC12216297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.